醫美板塊持續拉昇 奧園美谷等三股漲停 行業滲透率有望快速提升
格隆匯5月12日丨醫美板塊午後持續拉昇,澳洋健康、奧園美谷、華邦健康漲停,朗姿股份、國際醫學漲超7%,愛博醫療、金髮拉比、愛美客等跟漲。國金證券研報指出,未來數年將是醫美行業發展的黃金時期,看好醫美行業的整體擴和滲透率提升趨勢。業內人士認為,國內醫美市場的滲透率仍然較低,未來增長空間大。在2019年,國內醫美滲透率為3.6%,而韓國、美國以及日本這前三大醫美市場在2019年的醫美滲透率分別是20.5%、16.6%、11.0%。相較於國際成熟的醫美市場,國內醫美市場有望提升至2019年的3-5倍。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.